Oral herbal therapies for treating osteoarthritis
Identifieur interne : 000989 ( Main/Exploration ); précédent : 000988; suivant : 000990Oral herbal therapies for treating osteoarthritis
Auteurs : Melainie Cameron [Australie] ; Sigrun Chrubasik [Allemagne]Source :
- The Cochrane database of systematic reviews [ 1469-493X ] ; 2014.
Abstract
Medicinal plant products are used orally for treating osteoarthritis. Although their mechanisms of action have not yet been elucidated in full detail, interactions with common inflammatory mediators provide a rationale for using them to treat osteoarthritic complaints.
To update a previous Cochrane review to assess the benefits and harms of oral medicinal plant products in treating osteoarthritis.
We searched electronic databases (CENTRAL, MEDLINE, EMBASE, AMED, CINAHL, ISI Web of Science, World Health Organization Clinical Trials Registry Platform) to 29 August 2013, unrestricted by language, and the reference lists from retrieved trials.
Randomised controlled trials of orally consumed herbal interventions compared with placebo or active controls in people with osteoarthritis were included. Herbal interventions included any plant preparation but excluded homeopathy or aromatherapy products, or any preparation of synthetic origin.
Two authors used standard methods for trial selection and data extraction, and assessed the quality of the body of evidence using the GRADE approach for major outcomes (pain, function, radiographic joint changes, quality of life, withdrawals due to adverse events, total adverse events, and serious adverse events).
Forty-nine randomised controlled studies (33 interventions, 5980 participants) were included. Seventeen studies of confirmatory design (sample and effect sizes pre-specified) were mostly at moderate risk of bias. The remaining 32 studies of exploratory design were at higher risk of bias. Due to differing interventions, meta-analyses were restricted to
Five studies of three different extracts from
Six studies examined the ASU product Piasclidine®.Moderate-quality evidence from four studies (651 participants) indicated that ASU 300 mg produced a small and clinically questionable improvement in symptoms, and probably no increased adverse events compared to placebo after three to 12 months treatment. Mean pain with placebo was 40.5 points on a VAS 0 to 100 scale (0 is no pain), ASU 300 mg reduced pain by a mean of 8.5 points (95% CI 1 to 16 points); NNTB 8. ASU 300 mg improved function (standardised mean difference (SMD) −0.42, 95% CI −0.73 to −0.11). Function was estimated as 47 mm (0 to 100 mm scale, where 0 is no loss of function) with placebo, ASU 300 mg improved function by a mean of 7 mm (95% CI 2 to 12 mm); NNTB 5 (3 to 19). There were no differences in adverse events (5 studies, 1050 participants) between ASU (53%) and placebo (51%) (RR 1.04, 95% CI 0.97 to 1.12); withdrawals due to adverse events (1 study, 398 participants) between ASU (17%) and placebo (15%) (RR 1.14, 95% CI 0.73 to 1.80); or serious adverse events (1 study, 398 participants) between ASU (40%) and placebo (33%) (RR 1.22, 95% CI 0.94 to 1.59). Radiographic joint changes, measured as change in joint space width (JSW) in two studies (453 participants) did not differ between ASU 300 mg treatment (−0.53 mm) and placebo (−0.65 mm); mean difference of −0.12 (95% CI −0.43 to 0.19). Moderate-quality evidence from a single study (156 participants) confirmed possible benefits of ASU 600 mg over placebo, with no increased adverse events. Low-quality evidence (1 study, 357 participants) indicated there may be no differences in symptoms or adverse events between ASU 300 mg and chondroitin sulphate. Quality of life was not measured.
All other herbal interventions were investigated in single studies, limiting conclusions. No serious side effects related to any plant product were reported.
Evidence for the proprietary ASU product Piasclidine® in the treatment of osteoarthritis symptoms seems moderate to high for short term use, but studies over a longer term and against an apparently active control are less convincing. Several other medicinal plant products, including extracts of
There is no evidence that Piasclidine®significantly improves joint structure, and limited evidence that it prevents joint space narrowing. Structural changes were not tested for with any other herbal intervention.
Further investigations are required to determine optimum daily doses producing clinical benefits without adverse events.
Url:
DOI: 10.1002/14651858.CD002947.pub2
PubMed: 24848732
PubMed Central: 4494689
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000D59
- to stream Pmc, to step Curation: 000D58
- to stream Pmc, to step Checkpoint: 000751
- to stream Ncbi, to step Merge: 001697
- to stream Ncbi, to step Curation: 001697
- to stream Ncbi, to step Checkpoint: 001697
- to stream Main, to step Merge: 000989
- to stream Main, to step Curation: 000989
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oral herbal therapies for treating osteoarthritis</title>
<author><name sortKey="Cameron, Melainie" sort="Cameron, Melainie" uniqKey="Cameron M" first="Melainie" last="Cameron">Melainie Cameron</name>
<affiliation wicri:level="1"><nlm:aff id="A1">School of Health and Sport Sciences, Cluster for Health Improvement, University of the Sunshine Coast, Maroochydore DC, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>School of Health and Sport Sciences, Cluster for Health Improvement, University of the Sunshine Coast, Maroochydore DC</wicri:regionArea>
<wicri:noRegion>Maroochydore DC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chrubasik, Sigrun" sort="Chrubasik, Sigrun" uniqKey="Chrubasik S" first="Sigrun" last="Chrubasik">Sigrun Chrubasik</name>
<affiliation wicri:level="3"><nlm:aff id="A2">University of Freiburg, Freiburg, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>University of Freiburg, Freiburg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Fribourg-en-Brisgau</region>
<settlement type="city">Fribourg-en-Brisgau</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24848732</idno>
<idno type="pmc">4494689</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494689</idno>
<idno type="RBID">PMC:4494689</idno>
<idno type="doi">10.1002/14651858.CD002947.pub2</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000D59</idno>
<idno type="wicri:Area/Pmc/Curation">000D58</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000751</idno>
<idno type="wicri:Area/Ncbi/Merge">001697</idno>
<idno type="wicri:Area/Ncbi/Curation">001697</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001697</idno>
<idno type="wicri:Area/Main/Merge">000989</idno>
<idno type="wicri:Area/Main/Curation">000989</idno>
<idno type="wicri:Area/Main/Exploration">000989</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Oral herbal therapies for treating osteoarthritis</title>
<author><name sortKey="Cameron, Melainie" sort="Cameron, Melainie" uniqKey="Cameron M" first="Melainie" last="Cameron">Melainie Cameron</name>
<affiliation wicri:level="1"><nlm:aff id="A1">School of Health and Sport Sciences, Cluster for Health Improvement, University of the Sunshine Coast, Maroochydore DC, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>School of Health and Sport Sciences, Cluster for Health Improvement, University of the Sunshine Coast, Maroochydore DC</wicri:regionArea>
<wicri:noRegion>Maroochydore DC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chrubasik, Sigrun" sort="Chrubasik, Sigrun" uniqKey="Chrubasik S" first="Sigrun" last="Chrubasik">Sigrun Chrubasik</name>
<affiliation wicri:level="3"><nlm:aff id="A2">University of Freiburg, Freiburg, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>University of Freiburg, Freiburg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Fribourg-en-Brisgau</region>
<settlement type="city">Fribourg-en-Brisgau</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">The Cochrane database of systematic reviews</title>
<idno type="eISSN">1469-493X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title>
<p id="P1">Medicinal plant products are used orally for treating osteoarthritis. Although their mechanisms of action have not yet been elucidated in full detail, interactions with common inflammatory mediators provide a rationale for using them to treat osteoarthritic complaints.</p>
</sec>
<sec id="S2"><title>Objectives</title>
<p id="P2">To update a previous Cochrane review to assess the benefits and harms of oral medicinal plant products in treating osteoarthritis.</p>
</sec>
<sec id="S3"><title>Search methods</title>
<p id="P3">We searched electronic databases (CENTRAL, MEDLINE, EMBASE, AMED, CINAHL, ISI Web of Science, World Health Organization Clinical Trials Registry Platform) to 29 August 2013, unrestricted by language, and the reference lists from retrieved trials.</p>
</sec>
<sec id="S4"><title>Selection criteria</title>
<p id="P4">Randomised controlled trials of orally consumed herbal interventions compared with placebo or active controls in people with osteoarthritis were included. Herbal interventions included any plant preparation but excluded homeopathy or aromatherapy products, or any preparation of synthetic origin.</p>
</sec>
<sec id="S5"><title>Data collection and analysis</title>
<p id="P5">Two authors used standard methods for trial selection and data extraction, and assessed the quality of the body of evidence using the GRADE approach for major outcomes (pain, function, radiographic joint changes, quality of life, withdrawals due to adverse events, total adverse events, and serious adverse events).</p>
</sec>
<sec id="S6"><title>Main results</title>
<p id="P6">Forty-nine randomised controlled studies (33 interventions, 5980 participants) were included. Seventeen studies of confirmatory design (sample and effect sizes pre-specified) were mostly at moderate risk of bias. The remaining 32 studies of exploratory design were at higher risk of bias. Due to differing interventions, meta-analyses were restricted to <italic>Boswellia serrata</italic>
(monoherbal) and avocado-soyabean unsaponifiables (ASU) (two herb combination) products.</p>
<p id="P7">Five studies of three different extracts from <italic>Boswellia serrata</italic>
were included. High-quality evidence from two studies (85 participants) indicated that 90 days treatment with 100 mg of enriched <italic>Boswellia serrata</italic>
extract improved symptoms compared to placebo. Mean pain was 40 points on a 0 to 100 point VAS scale (0 is no pain) with placebo, enriched <italic>Boswellia serrata</italic>
reduced pain by a mean of 17 points (95% confidence interval (CI) 8 to 26); number needed to treat for an additional beneficial outcome (NNTB) 2; the 95% CIs did not exclude a clinically significant reduction of 15 points in pain. Physical function was 33 points on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 0 to 100 point subscale (0 is no loss of function) with placebo, enriched <italic>Boswellia serrata</italic>
improved function by 8 points (95% CI 2 to 14); NNTB 4. Assuming a minimal clinically important difference of 10 points, we cannot exclude a clinically important benefit in some people. Moderate-quality evidence (one study, 96 participants) indicated that adverse events were probably reduced with enriched <italic>Boswellia serrata</italic>
(18/48 events versus 30/48 events with placebo; relative risk (RR) 0.60, 95% CI 0.39 to 0.92). Possible benefits of other <italic>Boswellia serrata</italic>
extracts over placebo were confirmed in moderate-quality evidence from two studies (97 participants) of <italic>Boswellia serrata</italic>
(enriched) 100 mg plus non-volatile oil, and low-quality evidence from small single studies of a 999 mg daily dose of <italic>Boswellia serrata</italic>
extract and 250 mg daily dose of enriched <italic>Boswellia serrata</italic>
. It was uncertain if a 99 mg daily dose of <italic>Boswellia serrata</italic>
offered benefits over valdecoxib due to the very low-quality evidence from a small single study. It was uncertain if there was an increased risk of adverse events or withdrawals with <italic>Boswellia serrata</italic>
extract due to variable reporting of results across studies. The studies reported no serious adverse events. Quality of life and radiographic joint changes were not measured.</p>
<p id="P8">Six studies examined the ASU product Piasclidine®.Moderate-quality evidence from four studies (651 participants) indicated that ASU 300 mg produced a small and clinically questionable improvement in symptoms, and probably no increased adverse events compared to placebo after three to 12 months treatment. Mean pain with placebo was 40.5 points on a VAS 0 to 100 scale (0 is no pain), ASU 300 mg reduced pain by a mean of 8.5 points (95% CI 1 to 16 points); NNTB 8. ASU 300 mg improved function (standardised mean difference (SMD) −0.42, 95% CI −0.73 to −0.11). Function was estimated as 47 mm (0 to 100 mm scale, where 0 is no loss of function) with placebo, ASU 300 mg improved function by a mean of 7 mm (95% CI 2 to 12 mm); NNTB 5 (3 to 19). There were no differences in adverse events (5 studies, 1050 participants) between ASU (53%) and placebo (51%) (RR 1.04, 95% CI 0.97 to 1.12); withdrawals due to adverse events (1 study, 398 participants) between ASU (17%) and placebo (15%) (RR 1.14, 95% CI 0.73 to 1.80); or serious adverse events (1 study, 398 participants) between ASU (40%) and placebo (33%) (RR 1.22, 95% CI 0.94 to 1.59). Radiographic joint changes, measured as change in joint space width (JSW) in two studies (453 participants) did not differ between ASU 300 mg treatment (−0.53 mm) and placebo (−0.65 mm); mean difference of −0.12 (95% CI −0.43 to 0.19). Moderate-quality evidence from a single study (156 participants) confirmed possible benefits of ASU 600 mg over placebo, with no increased adverse events. Low-quality evidence (1 study, 357 participants) indicated there may be no differences in symptoms or adverse events between ASU 300 mg and chondroitin sulphate. Quality of life was not measured.</p>
<p id="P9">All other herbal interventions were investigated in single studies, limiting conclusions. No serious side effects related to any plant product were reported.</p>
</sec>
<sec id="S7"><title>Authors’ conclusions</title>
<p id="P10">Evidence for the proprietary ASU product Piasclidine® in the treatment of osteoarthritis symptoms seems moderate to high for short term use, but studies over a longer term and against an apparently active control are less convincing. Several other medicinal plant products, including extracts of <italic>Boswellia serrata</italic>
, show trends of benefits that warrant further investigation in light of the fact that the risk of adverse events appear low.</p>
<p id="P11">There is no evidence that Piasclidine®significantly improves joint structure, and limited evidence that it prevents joint space narrowing. Structural changes were not tested for with any other herbal intervention.</p>
<p id="P12">Further investigations are required to determine optimum daily doses producing clinical benefits without adverse events.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
</country>
<region><li>Bade-Wurtemberg</li>
<li>District de Fribourg-en-Brisgau</li>
</region>
<settlement><li>Fribourg-en-Brisgau</li>
</settlement>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Cameron, Melainie" sort="Cameron, Melainie" uniqKey="Cameron M" first="Melainie" last="Cameron">Melainie Cameron</name>
</noRegion>
</country>
<country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Chrubasik, Sigrun" sort="Chrubasik, Sigrun" uniqKey="Chrubasik S" first="Sigrun" last="Chrubasik">Sigrun Chrubasik</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Bois/explor/OrangerV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000989 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000989 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Bois |area= OrangerV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:4494689 |texte= Oral herbal therapies for treating osteoarthritis }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24848732" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a OrangerV1
This area was generated with Dilib version V0.6.25. |